FOCUS ON CERVICAL CANCER

German Institute for Quality and Efficacy in Health Care (IQWiG) confirms benefit of human papilloma-virus (HPV) testing for preventing cervical cancer.

IQWiG published a new report 11th June 2014 confirming the benefit of using oncogenic HPV testing in primary screening of women for cervical cancer, compared to routine Pap-smear (cytology) alone. Testing for oncogenic HPV alone or together with cytology detects cervical precancerous lesions (CIN2,3) earlier, allowing for better patient management and reducing the number of patients with cervical cancer.

 

See more at:

https://www.iqwig.de/en/press/press_releases/press_releases/hpv_testing_iqwig_still_sees_indications_of_a_benefit_in_primary_screening.6128.html